Want to join the conversation?
$CELG said in addition to the EU, REVLIMID is indicated for treating patients with relapsed/refractory MCL in the US, Switzerland, Israel, Turkey, Australia and some countries in Latin America. REVLIMID is also indicated in some countries including the EU for treating multiple myeloma and myelodysplastic syndromes.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.